This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Genzyme Corporation, Inc.
Genzyme Corporation, Inc., a prominent player in the biotechnology industry, is headquartered in the United States. Founded in 1981, Genzyme has established itself as a leader in developing innovative therapies for rare genetic disorders, multiple sclerosis, and other serious conditions. The company operates primarily in North America and Europe, focusing on areas such as enzyme replacement therapy and gene therapy. Genzyme's core products, including Cerezyme and Fabrazyme, are distinguished by their ability to address unmet medical needs, providing patients with life-altering treatments. With a strong commitment to research and development, Genzyme has achieved significant milestones, including its acquisition by Sanofi in 2011, which further solidified its market position. Renowned for its dedication to patient care and scientific advancement, Genzyme continues to make a meaningful impact in the biopharmaceutical landscape.
DitchCarbon Score
How does Genzyme Corporation, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genzyme Corporation, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genzyme Corporation, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Sanofi, any climate commitments or emissions data may be influenced by the parent company's initiatives. Sanofi has set ambitious targets for carbon reduction, which are cascaded down to Genzyme. These include commitments to the Science Based Targets initiative (SBTi) and participation in the CDP (formerly the Carbon Disclosure Project). However, specific reduction targets or achievements for Genzyme itself have not been disclosed. The company is also aligned with the RE100 initiative, aiming for 100% renewable electricity, and is involved in the Race to Zero campaign, which focuses on achieving net-zero emissions. While Genzyme has not published its own emissions figures, it is expected to adhere to the broader climate strategies established by Sanofi, reflecting a commitment to sustainability and climate action within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genzyme Corporation, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
